Biogen Inc. (BIIB) 10-Year Financial Performance & Capital Metrics

BIIB • • Industrial / General

HealthcareLarge PharmaSpecialty BiopharmaceuticalsNeurology & Neuroscience Leaders

AboutBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.Show more

Revenue $9.68B -1.6%
EBITDA $3.16B +22.0%
Net Income $1.63B +40.6%
EPS (Diluted) 11.19 +40.4%
Gross Margin 76.12% +2.5%
EBITDA Margin 32.69% +24.1%
Operating Margin 25.74% +20.7%
Net Margin 16.87% +42.9%
ROE 10.36% +25.7%
ROIC 8.88% +6.3%
Debt/Equity 0.40 -20.0%
Interest Coverage 9.95 +17.1%

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓FCF machine: 26.0% free cash flow margin
✓Momentum leader: RS Rating 81 (top 19%)
✓High quality earnings: Operating CF exceeds net income
✓Healthy 5Y average net margin of 20.5%
✓Trading at only 1.5x book value

✗Weaknesses

✗Profits declining 22.6% over 5 years
✗Sales declining 7.6% over 5 years

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y-0.03%

5Y-7.62%

3Y-4.13%

TTM3.94%

Profit (Net Income) CAGR

10Y-5.7%

5Y-22.63%

3Y1.6%

TTM-0.41%

EPS CAGR

10Y-1%

5Y-18.66%

3Y2.47%

TTM-0.72%

ROCE

10Y Avg21.79%

5Y Avg13.88%

3Y Avg11.46%

Latest10.84%

Peer Comparison

Neurology & Neuroscience Leaders

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
BIIBBiogen Inc.	24.73B	168.57	15.06	-1.62%	16.11%	8.83%	10.17%	0.40

Profit & Loss

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Sales/Revenue+	10.76B	11.45B	12.27B	13.45B	14.38B	13.44B	10.98B	10.17B	9.84B	9.68B
Revenue Growth %	0.11%	0.06%	0.07%	0.1%	0.07%	-0.06%	-0.18%	-0.07%	-0.03%	-0.02%
Cost of Goods Sold+	1.24B	1.43B	1.63B	1.82B	1.96B	1.81B	2.11B	2.28B	2.53B	2.31B
COGS % of Revenue	0.12%	0.13%	0.13%	0.14%	0.14%	0.13%	0.19%	0.22%	0.26%	0.24%
Gross Profit+	9.52B	10.02B	10.64B	11.64B	12.42B	11.64B	8.87B	7.9B	7.3B	7.37B
Gross Margin %	0.88%	0.87%	0.87%	0.86%	0.86%	0.87%	0.81%	0.78%	0.74%	0.76%
Gross Profit Growth %	0.12%	0.05%	0.06%	0.09%	0.07%	-0.06%	-0.24%	-0.11%	-0.08%	0.01%
Operating Expenses+	4.63B	4.86B	5.3B	5.75B	5.38B	7.05B	6.08B	5.01B	5.2B	4.88B
OpEx % of Revenue	0.43%	0.42%	0.43%	0.43%	0.37%	0.52%	0.55%	0.49%	0.53%	0.5%
Selling, General & Admin	2.11B	1.95B	1.94B	2.11B	2.36B	2.52B	2.68B	2.41B	2.5B	2.39B
SG&A % of Revenue	0.2%	0.17%	0.16%	0.16%	0.16%	0.19%	0.24%	0.24%	0.25%	0.25%
Research & Development	2.01B	1.97B	2.37B	2.71B	2.77B	4.53B	3.4B	2.6B	2.7B	2.49B
R&D % of Revenue	0.19%	0.17%	0.19%	0.2%	0.19%	0.34%	0.31%	0.26%	0.27%	0.26%
Other Operating Expenses	506.5M	940.7M	988.1M	929.2M	250.5M	0	0	0	0	0
Operating Income+	4.89B	5.15B	5.35B	5.89B	7.04B	4.59B	2.79B	2.89B	2.1B	2.49B
Operating Margin %	0.45%	0.45%	0.44%	0.44%	0.49%	0.34%	0.25%	0.28%	0.21%	0.26%
Operating Income Growth %	0.23%	0.05%	0.04%	0.1%	0.2%	-0.35%	-0.39%	0.04%	-0.27%	0.19%
EBITDA+	5.49B	5.79B	6.07B	6.54B	7.51B	5.05B	3.28B	3.41B	2.59B	3.16B
EBITDA Margin %	0.51%	0.51%	0.49%	0.49%	0.52%	0.38%	0.3%	0.33%	0.26%	0.33%
EBITDA Growth %	0.19%	0.05%	0.05%	0.08%	0.15%	-0.33%	-0.35%	0.04%	-0.24%	0.22%
D&A (Non-Cash Add-back)	600.4M	637.2M	721.6M	650.5M	464.7M	457.2M	487.7M	518.4M	494.8M	673.2M
EBIT	5.01B	5.71B	5.89B	6.36B	7.28B	4.65B	3.44B	3.02B	1.88B	2.32B
Net Interest Income+	-73.4M	-196.6M	-172.3M	-88.1M	-67.4M	-180.5M	-242.6M	-157.3M	29.6M	-182.7M
Interest Income	22.1M	63.4M	78.5M	112.5M	120M	42M	11M	89.3M	276.5M	67.6M
Interest Expense	95.5M	260M	250.8M	200.6M	187.4M	222.5M	253.6M	246.6M	246.9M	250.3M
Other Income/Expense	-136.2M	-218.7M	-217M	11M	3.9M	459.8M	-1.01B	705.3M	-800.5M	-584.3M
Pretax Income+	4.75B	4.93B	5.13B	5.9B	7.05B	5.05B	1.78B	3.59B	1.3B	1.91B
Pretax Margin %	0.44%	0.43%	0.42%	0.44%	0.49%	0.38%	0.16%	0.35%	0.13%	0.2%
Income Tax+	1.16B	1.24B	2.46B	1.43B	1.16B	992.3M	52.5M	632.8M	135.3M	273.8M
Effective Tax Rate %	0.75%	0.75%	0.5%	0.75%	0.84%	0.79%	0.87%	0.85%	0.9%	0.86%
Net Income+	3.55B	3.7B	2.54B	4.43B	5.89B	4B	1.56B	3.05B	1.16B	1.63B
Net Margin %	0.33%	0.32%	0.21%	0.33%	0.41%	0.3%	0.14%	0.3%	0.12%	0.17%
Net Income Growth %	0.21%	0.04%	-0.31%	0.74%	0.33%	-0.32%	-0.61%	0.96%	-0.62%	0.41%
Net Income (Continuing)	3.59B	3.7B	2.67B	4.47B	5.89B	4.06B	1.73B	2.96B	1.16B	1.63B
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	2.1M	-11.5M	-14.7M	-8M	-4.1M	-14.2M	63.5M	-9.5M	0	0
EPS (Diluted)+	15.34	16.93	11.92	21.58	31.42	24.80	10.40	20.87	7.97	11.19
EPS Growth %	0.24%	0.1%	-0.3%	0.81%	0.46%	-0.21%	-0.58%	1.01%	-0.62%	0.4%
EPS (Basic)	15.38	16.96	11.94	21.62	31.47	24.86	10.44	20.97	8.02	11.20
Diluted Shares Outstanding	231.2M	218.8M	213M	205.3M	187.4M	161.3M	149.6M	146M	145.6M	145.9M
Basic Shares Outstanding	230.7M	218.4M	212.6M	204.9M	187.1M	160.9M	149.1M	145.3M	144.7M	145.7M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Total Current Assets+	6.7B	8.73B	7.87B	7.64B	8.38B	6.89B	7.86B	9.79B	6.86B	7.46B
Cash & Short-Term Investments	3.43B	4.9B	3.69B	3.54B	4.48B	2.61B	3.8B	4.89B	1.05B	2.38B
Cash Only	1.31B	2.33B	1.57B	1.22B	2.91B	1.33B	2.26B	3.42B	1.05B	2.38B
Short-Term Investments	2.12B	2.57B	2.12B	2.31B	1.56B	1.28B	1.54B	1.47B	0	0
Accounts Receivable	1.54B	1.74B	2.32B	2.49B	2.47B	2.33B	1.96B	2.14B	2.1B	1.87B
Days Sales Outstanding	52.27	55.54	68.98	67.43	62.72	63.18	65.2	76.65	77.93	70.5
Inventory	893.4M	1B	902.7M	929.9M	804.2M	1.07B	1.35B	1.34B	2.53B	2.46B
Days Inventory Outstanding	262.89	255.08	202.14	186.87	150.11	216.06	233.82	215.38	364.14	388.71
Other Current Assets	286.3M	276.3M	304.4M	687.6M	631M	881.1M	740.8M	1.42B	1.18B	752.5M
Total Non-Current Assets+	12.8B	14.14B	15.78B	17.65B	18.85B	17.73B	16.02B	14.76B	19.99B	20.59B
Property, Plant & Equipment	2.19B	2.5B	3.18B	3.6B	3.67B	3.84B	3.79B	3.7B	3.73B	3.54B
Fixed Asset Turnover	4.92x	4.58x	3.86x	3.74x	3.91x	3.50x	2.90x	2.75x	2.64x	2.74x
Goodwill	2.66B	3.67B	4.63B	5.71B	5.76B	5.76B	5.76B	5.75B	6.22B	6.48B
Intangible Assets	4.09B	3.81B	3.88B	3.12B	3.53B	3.08B	2.22B	1.85B	8.36B	9.69B
Long-Term Investments	2.76B	2.83B	3.06B	1.38B	1.41B	772.1M	892M	705.7M	0	226.7M
Other Non-Current Assets	1.11B	1.34B	431.6M	1.69B	1.25B	2.9B	1.94B	1.53B	745M	333.8M
Total Assets+	19.5B	22.88B	23.65B	25.29B	27.23B	24.62B	23.88B	24.55B	26.84B	28.05B
Asset Turnover	0.55x	0.50x	0.52x	0.53x	0.53x	0.55x	0.46x	0.41x	0.37x	0.34x
Asset Growth %	0.36%	0.17%	0.03%	0.07%	0.08%	-0.1%	-0.03%	0.03%	0.09%	0.04%
Total Current Liabilities+	2.58B	3.42B	3.37B	3.3B	4.86B	3.74B	4.3B	3.27B	3.43B	5.53B
Accounts Payable	267.4M	279.8M	395.5M	370.5M	530.8M	454.9M	589.2M	491.5M	403.3M	424.2M
Days Payables Outstanding	78.69	71.26	88.56	74.45	99.08	91.98	101.94	78.74	58.11	67.02
Short-Term Debt	4.8M	4.7M	3.2M	0	1.5B	0	999.1M	0	150M	1.75B
Deferred Revenue (Current)	1000K	0	0	0	0	0	0	0	0	0
Other Current Liabilities	215.1M	282.9M	297.7M	320.9M	315.8M	515.3M	345.1M	1.14B	335.1M	375.8M
Current Ratio	2.60x	2.55x	2.34x	2.32x	1.72x	1.84x	1.83x	2.99x	2.00x	1.35x
Quick Ratio	2.25x	2.26x	2.07x	2.04x	1.56x	1.55x	1.51x	2.58x	1.26x	0.90x
Cash Conversion Cycle	236.48	239.37	182.56	179.85	113.76	187.27	197.09	213.29	383.96	392.19
Total Non-Current Liabilities+	7.55B	7.33B	7.69B	8.96B	9.03B	10.19B	8.62B	7.89B	8.61B	5.8B
Long-Term Debt	6.52B	6.51B	5.93B	5.94B	4.46B	7.43B	6.27B	6.28B	6.79B	4.55B
Capital Lease Obligations	0	0	0	0	412.7M	402M	330.4M	333M	400M	334.5M
Deferred Tax Liabilities	124.9M	93.1M	122.6M	1.64B	2.81B	1.03B	694.5M	334.7M	641.8M	190.5M
Other Non-Current Liabilities	905.8M	722.5M	1.63B	1.39B	1.35B	1.33B	1.32B	944.2M	781.1M	732.3M
Total Liabilities	10.13B	10.75B	11.05B	12.26B	13.9B	13.93B	12.92B	11.17B	12.05B	11.33B
Total Debt+	6.53B	6.52B	5.94B	5.94B	6.37B	7.83B	7.6B	6.61B	7.34B	6.63B
Net Debt	5.22B	4.19B	4.36B	4.71B	3.45B	6.5B	5.34B	3.19B	6.29B	4.26B
Debt / Equity	0.70x	0.54x	0.47x	0.46x	0.48x	0.73x	0.69x	0.49x	0.50x	0.40x
Debt / EBITDA	1.19x	1.13x	0.98x	0.91x	0.85x	1.55x	2.32x	1.94x	2.83x	2.10x
Net Debt / EBITDA	0.95x	0.72x	0.72x	0.72x	0.46x	1.29x	1.63x	0.94x	2.43x	1.35x
Interest Coverage	51.21x	19.81x	21.31x	29.35x	37.58x	20.64x	11.01x	11.72x	8.49x	9.95x
Total Equity+	9.37B	12.13B	12.6B	13.03B	13.34B	10.69B	10.96B	13.39B	14.8B	16.72B
Equity Growth %	-0.13%	0.29%	0.04%	0.03%	0.02%	-0.2%	0.03%	0.22%	0.11%	0.13%
Book Value per Share	40.55	55.43	59.15	63.48	71.16	66.25	73.26	91.70	101.64	114.57
Total Shareholders' Equity	9.37B	12.14B	12.61B	13.04B	13.34B	10.7B	10.9B	13.4B	14.8B	16.72B
Common Stock	100K	100K	100K	100K	100K	100K	100K	100K	100K	100K
Retained Earnings	12.21B	15.07B	15.81B	16.26B	16.46B	13.98B	13.91B	16.47B	17.63B	19.26B
Treasury Stock	-2.61B	-2.61B	-2.98B	-2.98B	-2.98B	-2.98B	-2.98B	-2.98B	-2.98B	-2.98B
Accumulated OCI	-224M	-319.9M	-318.4M	-240.4M	-135.2M	-299M	-106.7M	-164.9M	-153.7M	-136.2M
Minority Interest	2.1M	-11.5M	-14.7M	-8M	-4.1M	-14.2M	63.5M	-9.5M	0	0

Cash Flow

	Dec 2015	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024
Cash from Operations+	3.72B	4.52B	4.55B	6.19B	7.08B	4.23B	3.64B	1.38B	1.55B	2.88B
Operating CF Margin %	0.35%	0.4%	0.37%	0.46%	0.49%	0.31%	0.33%	0.14%	0.16%	0.3%
Operating CF Growth %	0.26%	0.22%	0.01%	0.36%	0.14%	-0.4%	-0.14%	-0.62%	0.12%	0.86%
Net Income	3.59B	3.7B	2.67B	4.47B	5.89B	4.06B	1.73B	2.96B	1.16B	1.63B
Depreciation & Amortization	600.4M	682.7M	1.08B	650.5M	464.6M	457.2M	487.7M	518.4M	494.8M	673.2M
Stock-Based Compensation	161.4M	154.8M	128M	157.5M	182.3M	198.3M	238.6M	254.1M	264.2M	291.2M
Deferred Taxes	-145.6M	-175M	91.7M	108.3M	67.1M	149M	-426.8M	-168.6M	-305.8M	-158.1M
Other Non-Cash Items	82.2M	91.2M	344.8M	397.2M	276.7M	-448M	1.76B	-1.29B	581.2M	592.2M
Working Capital Changes	-575.5M	73M	235.4M	400.2M	199.3M	-187.2M	-145.5M	-890.3M	-648.7M	-155.2M
Change in Receivables	-2.1M	-227.5M	-667.6M	-199.5M	5.5M	179.5M	326M	-222.4M	56.7M	194.2M
Change in Inventory	-174.4M	-165.6M	-94.5M	-52.1M	-19.2M	-316.3M	-462.4M	-320.2M	-130.9M	-273.8M
Change in Payables	0	0	0	0	0	0	0	0	0	0
Cash from Investing+	-4.55B	-2.48B	-2.96B	-2.05B	470.5M	-608.6M	-563.7M	1.59B	-4.09B	-799.2M
Capital Expenditures	-643M	-727.7M	-1.96B	-886.1M	-669.5M	-551.8M	-294.9M	-243.2M	-311.4M	-359.8M
CapEx % of Revenue	0.06%	0.06%	0.16%	0.07%	0.05%	0.04%	0.03%	0.02%	0.03%	0.04%
Acquisitions	-	-	-	-	-	-	-	-	-	-
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	-909.9M	-1.22B	-1.21B	-1.5B	-273M	-26.9M	12.9M	24.4M	-11.3M	83.9M
Cash from Financing+	986.4M	-987.8M	-2.38B	-4.47B	-5.86B	-5.27B	-2.09B	-1.76B	137M	-683.5M
Debt Issued (Net)	-	-	-	-	-	-	-	-	-	-
Equity Issued (Net)	-	-	-	-	-	-	-	-	-	-
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	-	-	-	-	-	-	-	-	-	-
Other Financing	3.8M	-28.8M	-453.7M	-116.2M	7.9M	-56.4M	-115.5M	-5.6M	-6M	-2.2M
Net Change in Cash	-	-	-	-	-	-	-	-	-	-
Free Cash Flow+	3.07B	3.86B	3.68B	5.3B	6.56B	3.81B	3.38B	1.14B	1.24B	2.52B
FCF Margin %	0.29%	0.34%	0.3%	0.39%	0.46%	0.28%	0.31%	0.11%	0.13%	0.26%
FCF Growth %	0.17%	0.26%	-0.05%	0.44%	0.24%	-0.42%	-0.11%	-0.66%	0.08%	1.04%
FCF per Share	13.29	17.64	17.29	25.82	35.03	23.59	22.61	7.84	8.49	17.24
FCF Conversion (FCF/Net Income)	1.05x	1.22x	1.79x	1.40x	1.20x	1.06x	2.34x	0.45x	1.33x	1.76x
Interest Paid	0	0	0	0	0	272.7M	280.8M	262.5M	252.2M	245.4M
Taxes Paid	0	0	0	0	0	906.7M	247.9M	932.9M	740.7M	355.1M

Key Ratios

Metric	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Return on Equity (ROE)	35.13%	34.44%	20.54%	34.57%	44.67%	33.31%	14.38%	25.03%	8.24%	10.36%
Return on Invested Capital (ROIC)	29.59%	25%	24.09%	25.45%	30.59%	20.28%	12.5%	13.18%	8.35%	8.88%
Gross Margin	88.48%	87.48%	86.72%	86.5%	86.4%	86.57%	80.79%	77.61%	74.24%	76.12%
Net Margin	32.95%	32.34%	20.69%	32.93%	40.96%	29.76%	14.17%	29.95%	11.81%	16.87%
Debt / Equity	0.70x	0.54x	0.47x	0.46x	0.48x	0.73x	0.69x	0.49x	0.50x	0.40x
Interest Coverage	51.21x	19.81x	21.31x	29.35x	37.58x	20.64x	11.01x	11.72x	8.49x	9.95x
FCF Conversion	1.05x	1.22x	1.79x	1.40x	1.20x	1.06x	2.34x	0.45x	1.33x	1.76x
Revenue Growth	10.93%	6.36%	7.21%	9.61%	6.88%	-6.49%	-18.32%	-7.36%	-3.32%	-1.62%

Revenue by Segment

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
MS Product Revenues	-	-	-	8.6B	8.53B	7.83B	6.1B	5.43B	4.66B	4.35B
MS Product Revenues Growth	-	-	-	-	-0.77%	-8.17%	-22.16%	-10.93%	-14.15%	-6.69%
TYSABRI product	1.89B	1.96B	1.97B	1.86B	1.89B	1.95B	2.06B	2.03B	1.88B	1.72B
TYSABRI product Growth	-	4.12%	0.47%	-5.53%	1.51%	2.85%	6.01%	-1.56%	-7.58%	-8.63%
Fumarate	-	-	-	-	-	3.91B	2.36B	2B	1.59B	1.6B
Fumarate Growth	-	-	-	-	-	-	-39.51%	-15.45%	-20.45%	0.40%
SPINRAZA	-	4.6M	883.7M	1.72B	2.1B	2.05B	1.91B	1.79B	1.74B	1.57B
SPINRAZA Growth	-	-	19110.87%	95.11%	21.62%	-2.14%	-7.16%	-5.86%	-2.92%	-9.65%
Interferon	-	-	-	2.36B	2.1B	1.88B	1.57B	1.31B	1.11B	968M
Interferon Growth	-	-	-	-	-11.05%	-10.67%	-16.59%	-16.65%	-15.30%	-12.45%

Revenue by Geography

	2015	2016	2017	2018	2019	2020	2021	2022	2023	2024
Non-US	2.64B	2.77B	3.34B	-	4.67B	4.79B	5.04B	4.52B	-	3.98B
Non-US Growth	-	4.72%	20.60%	-	-	2.70%	5.20%	-10.37%	-	-
UNITED STATES	2.91B	3.17B	3.29B	1.9B	6.71B	5.9B	3.81B	3.47B	3.14B	3.24B
UNITED STATES Growth	-	8.98%	3.93%	-42.22%	252.73%	-12.12%	-35.50%	-8.84%	-9.45%	3.05%
Europe	-	-	-	3.37B	-	-	-	-	2.13B	-
Europe Growth	-	-	-	-	-	-	-	-	-	-
GERMANY	-	-	-	-	-	-	-	-	868M	-
GERMANY Growth	-	-	-	-	-	-	-	-	-	-
Asia	-	-	-	281.2M	-	-	-	-	649.4M	-
Asia Growth	-	-	-	-	-	-	-	-	-	-

Frequently Asked Questions

Valuation & Price

Biogen Inc. (BIIB) has a price-to-earnings (P/E) ratio of 15.1x. This is roughly in line with market averages.

Growth & Financials

Biogen Inc. (BIIB) reported $9.99B in revenue for fiscal year 2024. This represents a 98% increase from $5.05B in 2011.

Biogen Inc. (BIIB) saw revenue decline by 1.6% over the past year.

Yes, Biogen Inc. (BIIB) is profitable, generating $1.61B in net income for fiscal year 2024 (16.9% net margin).

Dividend & Returns

Biogen Inc. (BIIB) has a return on equity (ROE) of 10.4%. This is reasonable for most industries.

Biogen Inc. (BIIB) generated $2.28B in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.

US Stock Screener

...